N@N

SAN DIEGO--([ BUSINESS WIRE ])--Santarus, Inc. (NASDAQ: SNTS) today announced that it has increased its revolving line of credit with Comerica Bank from $25 million to $35 million and extended the maturity from July 11, 2013 to February 13, 2015. In addition, Santarus has improved the interest terms on outstanding indebtedness under the credit facility with the option of paying either Comericaas prime rate (representing a reduction of 0.5%) or the LIBOR rate plus 2.25% (representing a reduction of 0.75%). Santarus makes interest-only payments on any draws from the line of credit and any principal outstanding is due and payable at the maturity date. Santarus has drawn $10 million on the line of credit to date.

"We are pleased to extend our commercial banking relationship with Comerica, and we look forward to Comericaas continued support as we focus on growing our business."

aThe revolving line of credit provides an attractive source of non-dilutive capital, and the increased size and improved terms give us flexibility in furthering our corporate objectives,a said Debra P. Crawford, senior vice president and chief financial officer of Santarus. aWe are pleased to extend our commercial banking relationship with Comerica, and we look forward to Comericaas continued support as we focus on growing our business.a

Santarus originally established the line of credit with Comerica in July 2006 to have capital available for working capital needs and other corporate purposes. The credit facility is secured by Santarusa assets, excluding intellectual property, and contains affirmative and negative covenants, including certain financial covenants.

About Santarus

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The companyas current commercial efforts are focused on [ GLUMETZA ] (metformin hydrochloride extended release tablets) and [ CYCLOSET ] (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes, and on [ FENOGLIDE ] (fenofibrate) tablets, which is indicated as an adjunct to diet to reduce high cholesterol.

Santarus also has a diverse pipeline, including three investigational drugs in late-stage clinical development: UCERIS^a" (budesonide) tablets for induction of remission of active ulcerative colitis, RHUCIN (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX for treatment of travelersa diarrhea, in addition to other earlier-stage development programs. More information about Santarus is available at [ www.santarus.com ].

Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans will be achieved.Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarusa business, including, without limitation: the potential for any debt that Santarus incurs under the line of credit to impair its ability to obtain additional financing in the future; Santarusa ability to satisfy the conditions to borrowing under the line of credit; Santarusa ability to comply with the covenants under the line of credit; the potential for an event of default under the line of credit, and the corresponding risk of acceleration of repayment and potential foreclosure on the assets pledged to secure the line of credit; difficulties or delays in development, testing, manufacturing and marketing of, and maintaining regulatory approvals for, Santarusa products; and other risks detailed in Santarusa prior press releases as well as in public periodic filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Santarus, FENOGLIDE and UCERIS^a" are trademarks of Santarus, Inc.GLUMETZA is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc.CYCLOSET is a trademark of VeroScience LLC.MMX is a trademark of Cosmo Technologies Limited. RHUCIN is a trademark of Pharming Group NV.